|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:annualSalesPeak
|
over $20 billion
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
L04AB04
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:blackBoxWarning
|
malignancy
serious infections
|
|
gptkbp:cost
|
high
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:firstApprovalAgency
|
gptkb:FDA
|
|
gptkbp:firstBiosimilarApprovalEU
|
2017
|
|
gptkbp:firstBiosimilarApprovalUS
|
2023
|
|
gptkbp:form
|
solution for injection
pre-filled syringe
pen injector
|
|
gptkbp:genericName
|
gptkb:adalimumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Humira
|
|
gptkbp:indication
|
gptkb:juvenile_idiopathic_arthritis
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
uveitis
ankylosing spondylitis
plaque psoriasis
hidradenitis suppurativa
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:AbbVie
|
|
gptkbp:market
|
blockbuster drug
|
|
gptkbp:mechanismOfAction
|
TNF inhibitor
|
|
gptkbp:molecularWeight
|
148 kDa
|
|
gptkbp:patentExpiryUS
|
2016
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:product
|
gptkb:monoclonal_antibody
|
|
gptkbp:riskFactor
|
tuberculosis
increased risk of infection
reactivation of hepatitis B
risk of malignancy
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
headache
injection site reaction
rash
upper respiratory infection
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:AbbVie
gptkb:Cambridge_Antibody_Technology
|
|
gptkbp:bfsLayer
|
6
|